PellePharm Completes Enrollment Of Pivotal Phase 3 Clinical Trial Of Patidegib Topical Gel In Patients With Gorlin Syndrome
SAN FRANCISCO– December 2, 2019– PellePharm, Inc., a BridgeBio Pharma, Inc. (Nasdaq: BBIO) company, today announced the completion of enrollment for its pivotal Phase 3 clinical trial of Patidegib Topical Gel 2% vs. vehicle gel in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 2, 2019 Category: Pharmaceuticals Source Type: clinical trials
An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
Condition: Recurrent Basal Cell Carcinoma Interventions: Drug: Patidegib Topical Gel, 2%; Drug: Patidegib Topical Gel, Vehicle Sponsor: PellePharm, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2019 Category: Research Source Type: clinical trials
